International Stem Cell Corp. is focused on treating diseases of the eye, nervous system, and liver by utilizing a new stem cell technology called parthenogenesis. The regenerative technology uses unfertilized eggs, sidestepping the controversial use of embryo stem cells, to address immune-rejection.
Stem cells not only have the ability to proliferate, but also to change (differentiate) into more specialized cells such as skin, liver, or blood cells. Because these "pluripotent" stem cells have the potential to become any cell in the body, they are considered the most powerful stem cells.
The first type of pluripotent stem cells to be studied were embryonic stem cells, though the process is of considerable ethical question because creating embryonic stem cells involves the destruction of a fertilized human embryo.
As an innovative alternative, ISCO has pioneered the development of human parthenogenetic stem cells (hpSCs), which are created by chemically stimulating unfertilized eggs (oocytes) to initiate division (proliferation). hpSCs are one of four of the most commonly used and described classes of stem cells: embryonic stem cells (embryonic SCs), induced pluripotent stem cells (iPS), and adult stem cells (adult SCs).
The parthenogenetic stem cells developed by ISCO are the only class of cells that meet all the criteria considered for therapeutic applications. The company has developed a UniStemCell bank, the life science industry's first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The company anticipates that in the medium term, revenue could be generated through the franchise of stem cell banks.
For more information, visit internationalstemcell.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net